Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
2023 · Molecular Cancer · 122 citations
https://doi.org/10.1186/s12943-023-01722-0
A
Aimin Jiang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
110
Papers
1.3K
Citations
20
h-index
34
i10-index
Aimin Jiang is an academic researcher from Universiti Sains Malaysia. The author has contributed to research in topics: Renal cell carcinoma treatment & Ferroptosis and cancer prognosis & Cancer Immunotherapy and Biomarkers. The author has an h-index of 20, co-authored 94 publications.
ORCID: 0000-0002-9563-983XPapers by this author
worksCTLs heterogeneity and plasticity: implications for cancer immunotherapy
2024 · Molecular Cancer · 91 citations
https://doi.org/10.1186/s12943-024-01972-6
Intratumoral mycobiome heterogeneity influences the tumor microenvironment and immunotherapy outcomes in renal cell carcinoma
2025 · Science Advances · 24 citations
https://doi.org/10.1126/sciadv.adu1727
Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment
2024 · Advanced Science · 22 citations
https://doi.org/10.1002/advs.202403423
Computational frameworks transform antagonism to synergy in optimizing combination therapies
2025 · npj Digital Medicine · 17 citations
https://doi.org/10.1038/s41746-025-01435-2
Protein Spatial Structure Meets Artificial Intelligence: Revolutionizing Drug Synergy–Antagonism in Precision Medicine
2025 · Advanced Science · 8 citations
https://doi.org/10.1002/advs.202507764
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat